doxorubicin hydrochloride / Generic mfg. - LARVOL DELTA

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Ou Bai, MD/PHD

New P2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CD20 • MYC

Ataxia telangiectasia and Rad3 related kinase inhibitors and gemcitabine induce synergistic killing of uterine leiomyosarcoma cells (AACR 2026) - "Therefore, we investigated the potential for ATR inhibitors to enhance the potency and efficacy of chemotherapy for uLMS in vitro. CellTitre Glo, Bliss Independence analysis, and Multidimensional Synergy of Combinations (MuSyC) assessed synergy between three ATRi (elimusertib, ceralasertib, berzosertib) and SOC chemotherapy (gemcitabine, doxorubicin, docetaxel) in three commercially available (SK-LMS-1, SK-UT-1B, SK-UT-1) and two patient-derived uLMS cell lines (ACI-44A, ACI-44B). Elimusertib strongly synergizes with gemcitabine in vitro across uLMS cell lines by potentiating DNA damage and apoptosis. The lack of synergy with docetaxel or doxorubicin underscores gemcitabine as the most effective combination with ATR inhibitors. These finds support further preclinical and clinical evaluation of elimusertib + gemcitabine as a promising novel therapy for uterine leiomyosarcoma."

Gynecologic Cancers • Leiomyosarcoma • Oncology • Sarcoma • Solid Tumor • Uterine Leiomyosarcoma • ANXA5 • ATR • CASP3 • CHEK1

SOUNDTRACK-D2: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (clinicaltrials.gov) - P3 | N=420 | Recruiting | Sponsor: AstraZeneca

Trial initiation date • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Large B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

P38 MAPK IN PODOCYTES REGULATES AUTOPHAGY VIA ULK1 PHOSPHORYLATION (ISN-WCN 2026) - "For in vitro experiments, cultured human podocytes with p38 MAPK knockout via CRISPR/Cas9 were exposed to adriamycin, and autophagy-related pathways were assessed by Western blot, focusing on autophagic flux and ULK1 phosphorylation status.Results Following immunotoxin-induced podocyte injury, proteinuria peaked at week 2 in control mice, whereas cKO mice exhibited significantly increased proteinuria at both weeks 1 and 2...Our findings suggest that p38 MAPK deficiency inhibits ULK1 phosphorylation, leading to autophagic dysfunction accompanied by energy metabolic disturbances, ultimately resulting in the worsened podocyte injury. These results highlight that p38 MAPK in podocytes plays a crucial role in maintaining podocyte homeostasis through the regulation of autophagy via ULK1 mediated-signaling."

Focal Segmental Glomerulosclerosis • Glomerulonephritis • Metabolic Disorders • Renal Disease • ATG7 • CASP3 • GABARAPL1 • LAMP1 • ULK1

Regenerated nephrons in kidney cortices ameliorates renal dysfunction in rats with kidney failure (ISN-WCN 2026) - "Model rats of RPKF and CKF were each created by systemic administration of Adriamycin of 6.0 mg/kg BW and 3.5 mg/kg BW...It remains unclear how long our K-CIT method will be effective for KF patients, however, our method can be repeated against the same damaged kidney without ethical issues and immunological subjects. We hope that our K-CIT will spread over the world as a new therapeutic method for KF."

Late-breaking abstract • Preclinical • Chronic Kidney Disease • Nephrology • Renal Disease

REGULATORY ROLE AND MECHANISM OF FNBP1L/FNBP1 ON CDC42 IN GLOMERULAR PODOCYTES (ISN-WCN 2026) - "Furthermore, their expression in podocytes was decreased in both in vivo and in vitro models induced by Adriamycin (ADR), Lipopolysaccharide (LPS), and Puromycin Aminonucleoside (PAN)...In glomerular diseases, the downregulation of FNBP1 and FNBP1L leads to loss of CDC42 expression and function, resulting in podocyte injury. Therefore, these proteins represent potential therapeutic targets for podocytopathies."

Chronic Kidney Disease • Diabetic Nephropathy • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • Renal Disease • CDC42

BIPHASIC KIDNEY INJURY DUE TO BEVACIZUMAB- AND DOXORUBICIN-ASSOCIATED RENAL-LIMITED THROMBOTIC MICROANGIOGRAPHY: A CASE REPORT (ISN-WCN 2026) - "It may be difficult to distinguish drug-induced TMA from other primary TMAs, and the principal treatment is withdrawal of the causative drug, which requires early recognition.Methods We report the case of a 52-year-old woman with metastatic ovarian serous adenocarcinoma who developed biphasic kidney dysfunction during chemotherapy with bevacizumab and pegylated liposomal doxorubicin (PLD). The patient was diagnosed with ovarian cancer nine years earlier and underwent hysterectomy, oophorectomy, colectomy, and adjuvant paclitaxel–carboplatin therapy...Recognition of characteristic renal histopathological findings is crucial in differentiating drug-induced TMA from other etiologies. Timely diagnosis allows prompt cessation of the offending drug, which may preserve kidney function and optimize patient outcomes during chemotherapy."

Case report • Clinical • Glomerulonephritis • Gynecology • Lupus Nephritis • Nephrology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Renal Disease • Solid Tumor

ADVANCING KIDNEY ORGANOID DEVELOPMENT FOR REGENERATIVE NEPHROLOGY: ENHANCING DIFFERENTIATION AND FUNCTIONALITY USING HIPSCS AND BIOPRINTING (ISN-WCN 2026) - "These organoids responded to nephrotoxic exposure (doxorubicin), indicating physiological relevance and functional maturation.Conclusion Combining chemical modulation with automated bioprinting significantly improves the differentiation and functional development of kidney organoids from hiPSCs. This integrated approach enhances reproducibility, scalability, and physiological relevance, offering a robust platform for nephrology research and future regenerative therapies."

Chronic Kidney Disease • Nephrology

CD93 IS A NOVEL ENDOTHELIAL PREDICTIVE AND THERAPEUTIC TARGET IN NEPHROTIC SYNDROME (ISN-WCN 2026) - "Additionally, we tested efficacy of CD93 blocking antibody in 2 models of proteinuria (podocyte-specific TGFb1 [TGFb1]and Adriamycin[ADR])...Cara Fuentes and Dr. Johnson are inventors on a pending patent on novel therapeutics for proteinuric kidney diseases.I did not use generative AI and AI-assisted technologies in the writing process."

Chronic Kidney Disease • Diabetic Nephropathy • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • CD93 • TGFB1

INTRAVASCULAR LARGE B-CELL LYMPHOMA DIAGNOSED BY RENAL BIOPSY PRESENTING WITH NEPHROTIC SYNDROME (ISN-WCN 2026) - "His past history included hypertension, dyslipidemia, and chronic obstructive pulmonary disease, treated with amlodipine, atorvastatin, indacaterol, and silodosin...R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) was initiated, followed by high-dose methotrexate for CNS prophylaxis...This case emphasizes the importance of considering hematologic malignancy in the differential diagnosis of nephrotic syndrome with unexplained fever, even in the absence of hematologic abnormalities. Early renal biopsy allowed timely R-CHOP chemotherapy and resulted in favorable clinical and renal outcomes."

Biopsy • B Cell Lymphoma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Diffuse Large B Cell Lymphoma • Dyslipidemia • Glomerulonephritis • Hematological Malignancies • Hypertension • Immunology • Large B Cell Lymphoma • Lymphoma • Metabolic Disorders • Nephrology • Non-Hodgkin’s Lymphoma • Pulmonary Disease • Renal Cell Carcinoma • Renal Disease • Respiratory Diseases • BCL6 • CD20 • IL2 • IRF4 • PTPRC

YIQI QINGRE GAO ALLEVIATES PODOCYTE INJURY VIA REGULATING AUTOPHAGY-NLRP3 INFLAMMASOME CROSSTALK (ISN-WCN 2026) - "The interaction between autophagy and NLRP3 inflammasome appears to be a potentially protective mechanism for podocytes.Methods An adriamycin (ADR)-induced mouse model of renal injury and a model of MPC-5 cell damage were employed, followed by intervention with YQQRG...Moreover, the addition of an overexpression plasmid NLRP3 and an autophagic inhibitor 3-MA attenuated the protective effect of YQQRG in ADR-stimulated MPC5 cells.Conclusion These findings indicate YQQRG protects podocytes via regulating the crosstalk between autophagy and NLRP3 inflammasome. Thus, YQQRG may be a therapeutic candidate for glomerular diseases."

Renal Disease • IL18 • IL1B • NLRP3

GLOMERULAR FRAGILITY AND VASCULAR BARRIER INSTABILITY INDUCED BY A COMMON EAST ASIAN LAMININ Β2 VARIANT: ROLE OF THE LF DOMAIN (ISN-WCN 2026) - "Glomerular stress was induced by adriamycin administration to evaluate barrier stability...Furthermore, ocular examination revealed abnormal corneal thickening and age-dependent retinal thinning, a phenotype suggestive of structural compromise of the blood-retinal barrier, which was not observed in wild-type mice.Conclusion This study conclusively demonstrates the in vivo pathogenicity of the common East Asian G699R allele and simultaneously reveals a previously unrecognized function of the Laminin β2 LF domain in renal and ocular vascular barrier maintenance, specifically demonstrating the critical role of laminin in endothelial cell integrity. Our findings highlight the importance of evaluating ethnically enriched variants in genetic risk assessment and disease modeling, which has significant implications for personalized precision medicine."

Glomerulonephritis • Nephrology • Renal Disease • LAMB2 • LAMC1

LOSS OF TRANSCRIPTION FACTOR ATOH8 ACTIVATES TGF-Β SIGNALING AND EXACERBATES GLOMERULOSCLEROSIS IN PODOCYTES (ISN-WCN 2026) - "The potential epigenetic regulation of ATOH8 expression and localization was examined using the EZH2 inhibitor GSK126. In vivo relevance was analyzed in adriamycin (ADR)-induced focal segmental glomerulosclerosis (FSGS) models in wild-type and Atoh8-deficient mice...Furthermore, the regulation of ATOH8 by the histone methyltransferase EZH2 suggests an epigenetic mechanism underlying its suppression. Together, these findings identify ATOH8 as a critical protective factor maintaining podocyte integrity and a potential therapeutic target for limiting glomerular injury."

ANCA Vasculitis • Chronic Kidney Disease • Diabetic Nephropathy • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Vasculitis • COL1A1 • COL4A1 • EZH2 • SMAD2 • SNAI1 • TGFB1

YI QI QING RE GAO ALLEVIATES PODOCYTE CYTOSKELETON DYSFUNCTION VIA TUBULE-PODOCYTE CROSSTALK MEDIATED BY RENAL TUBULAR SIRT1 (ISN-WCN 2026) - "This experiment used an ADR nephropathy model to observe the effects of YQQRG on glomeruli and tubules, and explored possible mechanism.Methods In vivo studies were conducted to construct conditional Sirt1 knockout mice of renal tubular epithelial cells, induced by Adriamycin (ADR) nephropathy model...This study elucidates the crosstalk between renal tubular epithelial cells and podocytes, providing scientific evidence for the use of Yiqi Qingre to reduce damage to renal tubular epithelial cells and podocytes, and to lower proteinuria. YQQRG may be a promising natural drug for treating kidney diseases."

CTTN • SIRT1

DUAL ROLES OF CCL5 ON PODOCYTES AND MACROPHAGES IN GLOMERULAR INJURY (ISN-WCN 2026) - "Cultured wild-type (WT) podocytes and CCL5 KO podocytes were treated with adriamycin (ADR), and apoptosis rates were evaluated...Bone marrow chimera experiments revealed that podocyte-derived CCL5 confers protection, whereas CCL5 from bone marrow-derived macrophages aggravates glomerular inflammation.Conclusion CCL5 plays dual roles in experimental nephropathy—protective in podocytes but pathogenic through macrophage activation. These results suggest that CCL5 has ambivalent roles in glomerular diseases, acting in a cell type-dependent manner and offering insight into cell-specific chemokine targeting as a potential therapeutic approach."

Bone Marrow Transplantation • Glomerulonephritis • Inflammation • Lupus Nephritis • CCL5 • NOTCH2

THE DISCOVERY AND ANALYSIS OF A UNIQUE SUBPOPULATION OF PROXIMAL TUBULAR CELLS EXHIBITING PHENOTYPES INDICATIVE OF SENESCENCE (ISN-WCN 2026) - "While recent research indicates that cellular senescence may play a role in the pathogenesis of kidney diseases, the precise identification of senescent cells in vivo remains challenging, and its significance is not yet fully understood.Methods We utilized transgenic mice specifically engineered to express the G0 marker, mVenus-p27K-, in proximal tubular cells (PTCs) (PTC-G0 mice) and the FUCCI2aR system in PTCs (PTC-FUCCI mice) to induce kidney injury models through the administration of aristolochic acid and cisplatin...Time-lapse imaging of primary PTCs from PTC-G0 mice treated with doxorubicin (DOXO) demonstrated sustained expression of the G0 marker, with permanent cell cycle arrest...In human kidney diseases, Cyclin D1-positive FR-PTCs accumulate concurrently with kidney dysfunction, serving as a potential predictor of adverse kidney prognosis. This work was first presented at ASN Kidney Week 2023, and re-submission is permitted by ASN.I have potential conflict of..."

Clinical • Nephrology • Renal Disease • CCND1 • RUNX1 • STAT1 • TP53

SPECTRUM OF KIDNEY INJURY ON RENAL BIOPSY FOLLOWING ANTICANCER DRUG TREATMENT (ISN-WCN 2026) - "Anticancer drugs used were TKI (Levatinib), Vincristine, cyclophosphamide, doxorubicin, etoposide; Paclitaxel Based Chemotherapy; Cyclophosphamide, Paclitaxel and Etoposide; and Capecitabine. On post renal biopsy follow-up of 1 month to 20 months, two patients succumbed; and two lost to follow-up.Conclusion Following anticancer drug treatment variety of lesions may be found affecting all renal compartments. Prompt diagnosis and treatment may prolong renal and patient survival."

Biopsy • Breast Cancer • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Lupus Nephritis • Nephrology • Oncology • Ovarian Cancer • Renal Disease • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma

COLLAPSING GLOMERULOPATHY DRIVEN BY ABERRANT ACTIVATION OF ERK1/2 (ISN-WCN 2026) - "Next, we established transgenic mice and cell lines in which ERK1/2 is constitutively phosphorylated in a doxycycline-dependent manner, specifically within podocytes...Similarly, in wild-type mice, p-ERK1/2 was identified in a subset of podocytes with aging and in the adriamycin-induced nephropathy model...Combined with strong ERK1/2 phosphorylation in podocytes in human collapsing glomerulopathy, these processes may contribute to the pathogenesis of this disease. Our findings underscore the role of ERK1/2 signaling as a pivotal mediator of podocyte pathology and suggest it as a potential therapeutic target for glomerular diseases characterized by podocyte injury and loss.This work was first presented at ASN Kidney Week 2025, and re-submission is permitted by ASN."

Chronic Kidney Disease • Diabetic Nephropathy • Glomerulonephritis • IgA Nephropathy

DOXORUBICIN INDUCES SUBCLINICAL AND THERAPEUTICALLY REVERSIBLE MITOCHONDRIAL INJURY IN RENAL TUBULAR CELLS REVEALED BY EX VIVO SEAHORSE ASSAY AND STRUCTURED ILLUMINATION MICROSCOPY (ISN-WCN 2026) - "Ex vivo seahorse assay shows DOX-induced mitochondrial dysfunction. (b) SIM shows DOX-induced mitochondrial fragmentation."

Preclinical • Cardiomyopathy • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease

Synthesis and antifungal and antitumor activities of acridine-containing tetrahydronaphthalene spiroisoxazoline derivatives. (PubMed, Mol Divers) - "In addition, cytotoxicity studies showed that these compounds exhibited relatively high toxicity against normal cells while exerting significant antiproliferative activity against human colorectal cancer cells; notably, compound 10e had the half-maximal inhibitory concentration value of 2.53 µM, which was higher than that of the positive controls Cisplatin (36.00 µM) and Doxorubicin (10.43 µM). These findings suggest that the novel acridine-containing tetrahydronaphthalene spiroisoxazoline derivatives with multiple active fragments hold promise as candidates for the development of new antifungal agents and antitumor drugs."

Journal • Colorectal Cancer • Oncology • Solid Tumor

Systems-level integration of machine learning, SHAP explainability, PCA, and network topology reveals multitarget protective actions of tannic acid against doxorubicin toxicity in pentose phosphate pathway. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The classifier achieved excellent discriminative performance, with a low out-of-bag Brier score (0.138). TA demonstrates a protective effect against DOX-induced oxidative stress and enzymatic impairment in the rat lung, suggesting its potential as a supportive therapeutic agent."

Journal • G6PD • IL6 • PGD

Anti-EGFR Aptamer-Conjugated Erythrocyte Membrane-Derived Nanoparticles for Targeted Doxorubicin Delivery. (PubMed, Mol Pharm) - "In vivo therapeutic evaluation in a tumor xenograft mouse model demonstrated significant tumor growth inhibition and a favorable safety profile compared with the free drug. These findings suggest that substituting antibodies with aptamers represents a crucial advancement in developing more stable, less immunogenic, and highly efficient targeted nanomedicines for clinical translation in cancer therapy."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

CD44 Receptor-Mediated Delivery of ROS/pH Dual-Sensitive Nanoparticles Based on Poly(Ethylene Glycol)-b-Poly(Doxorubicin)-b-Hyaluronic Acid Copolymer. (PubMed, Int J Nanomedicine) - "PPDHA nanoparticles demonstrated tumor-specific delivery and superior anticancer efficacy in vitro and in vivo. These findings suggest that PPDHA nanoparticles are promising candidates for targeted anticancer drug delivery."

Journal • Breast Cancer • Oncology • Solid Tumor

Comprehensive toxicity profile of the 4AC-4THP neoadjuvant regimen in HER2-positive breast cancer: a multicenter real-world study in Vietnam. (PubMed, Front Oncol) - "The 4AC-4THP regimen-comprising doxorubicin and cyclophosphamide followed by docetaxel, trastuzumab, and pertuzumab-has been widely adopted as neoadjuvant treatment for HER2-positive breast cancer. Subclinical cardiac dysfunction was common but mild and manageable. These findings provide further support for its use in neoadjuvant settings with appropriate monitoring strategies, especially in real-world clinical settings with variable access to monitoring resources."

Clinical • Journal • Real-world evidence • Alopecia • Anorexia • Breast Cancer • Cardiovascular • Congestive Heart Failure • Fatigue • Heart Failure • HER2 Breast Cancer • HER2 Positive Breast Cancer • Immunology • Mucositis • Neutropenia • Pain • Solid Tumor • Stomatitis • Thrombocytopenia • HER-2

Ultrasound-triggered doxorubicin targeted delivery for liver cancer treatment: Reduced toxicity and improved efficacy. (PubMed, PLoS One) - "The effects of ultrasound-enhanced drug delivery to HepG2 cells demonstrated that the combination of ultrasound and targeted liposomes significantly increased the internalization of the drug (DOX) and triggered apoptosis in HepG2 cells, leading to cell death. Morphological observations on treated cells via phase contrast microscopy supported the signs of apoptosis, indicating LL's potential to target liver cancer cells effectively."

Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • ASGR • MUC4